Alembic Pharmaceuticals has reported results for second quarter ended September 30, 2012.
On standalone basis, the company has posted a rise of 9.13% in its net profit at Rs 41.47 crore for the quarter ended September 30, 2012 as compared to Rs 38.00 crore for the same quarter in the previous year. Total income has increased by 5.64% at Rs 406.85 crore for quarter under review as compared to Rs 385.12 crore for the quarter ended September 30, 2011.
On consolidated basis, the company has posted a rise of 11.70% in its net profit at Rs 42.49 crore for the quarter ended September 30, 2012 as compared to Rs 38.04 crore for the same quarter in the previous year. Total income has increased by 2.23% at Rs 406.85 crore for quarter under review as compared to Rs 397.99 crore for the quarter ended September 30, 2011.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1688.75 |
Dr. Reddys Lab | 1108.55 |
Cipla | 1433.45 |
Lupin | 1982.65 |
Zydus Lifesciences | 859.55 |
View more.. |